Informaçao sobre o Autor

Новик, А. В

Edição Seção Título Arquivo
Nº 8 (2016) Articles COMBINATION OF VEMURAFENIB+KOBIMETINIB FUNDAMENTALLY CHANGES PROGNOSIS FOR METASTATIC MELANOMA
Nº 17 (2016) Articles ROLE OF NEW ANTIANGIOGENIC DRUGS IN THE SECOND-LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER
Nº 7 (2018) Articles PRINCIPLES OF MODERN IMMUNOTHERAPY
Volume 26, Nº 7 (2019) Articles Prognostic markers for testicular germ cell tumors. Research perspectives
Volume 26, Nº 7 (2019) Articles The role of peripheral blood immunological parameters as predictive markers in cancer patients: the prognostic role of the neutrophil/lymphocyte ratio
Volume 26, Nº 7 (2019) Articles Modern immunotherapy for kidney cancer
Volume 26, Nº 7 (2019) Articles PEComas: what are the treatment options? Literature review and personal experience
Volume 27, Nº 7 (2020) Articles Comparison of systems for evaluating the effectiveness of modern immunotherapy
Volume 27, Nº 11 (2020) Articles Ten-year experience of pharmacotherapy for soft tissue sarcomas
Volume 27, Nº 11 (2020) Articles The use of panitumumab in the treatment of chemoresistant metastatic sigmoid colon adenocarcinoma: a clinical case
Volume 28, Nº 7 (2021) Articles Experience of using prolgolimab in real clinical practice
Volume 28, Nº 7 (2021) Articles Immunological aspects of metronomic chemotherapy regimens
Volume 28, Nº 7 (2021) Articles Assessment of the dynamics of immunological parameters at the beginning of therapy as prognostic and predictive factors in patients with melanoma
Volume 28, Nº 11 (2021) Articles Neoadjuvant immunotherapy for non-small cell lung cancer
Volume 29, Nº 7 (2022) Articles The use of pazopanib in the treatment of disseminated soft tissue sarcoma: personal experience
Volume 29, Nº 11/12 (2022) Articles Possibilities of the combination of avelumab and axitinib in the first line in patients with advanced renal cell carcinoma

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies